Institute for Myeloma & Bone Cancer Research(Dr.James Berenson), West Hollywood, CA - In a study of 100 of his patients his 5 year survival rate is 89.7%* vs. the SEER data of 40.9%. This is the best 5 year life expectancy yet presented on this site. This means you are 5.7* time...
Myeloma is the second most common blood cancer, but it is not a common cancer. An estimated 32,110 new patients will be diagnosed with myeloma in the United States in 2019, and men are diagnosed with the condition slightly more frequently than women. The mortality statistic in the U.S. i...
Multiple myeloma is a type ofcancerof the plasma cells (a type of white blood cells) of the bone marrow. Plasma cells are protein-making cells that normally produce the different kinds of antibodies of the disease-fighting immune system. In multiple myeloma, the plasma cells undergo a malignan...
SURVIVAL ratePROGRESSION-free survivalPROGNOSISOVERALL survivalPurpose: The incidence of multiple myeloma (MM) is rising and there are fewer Indian studies; a comprehensive research of MM patients' survival data in a real-world population is needed. This study aims to analyze the survival status of...
BMC Cancer volume 24, Article number: 541 (2024) Cite this article 1801 Accesses 12 Altmetric Metrics details Abstract Objectives The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among ...
Cancer therapeutic resistanceMyelomaDespite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as ...
AI-Driven Model For Identifying Cancer Cachexia Survival Outcomes May Improve When Treatment Is Guided by Using Both Tissue and Liquid Biopsies Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource Limited Settings ...
IL-6 overexpressed either by the myeloma cells themselves or by stromal cells in the BM appears to drive the development and maintenance of the cancer. Indeed, the binding of myeloma cells to receptors on bone marrow stromal cells stimulates the synthesis of IL-6 by the latter. As well as ...
The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer. 2012;106(3):546–52. Article PubMed PubMed Central CAS Google Scholar Muthu Raja KR, Rihova L, Zahradova L, Klincova M, ...
Several models have studied the many ways therapies can be applied in an adaptive manner ensuring that the competition between treatment-resistant and naïve populations allows for better overall survival for cancer patients. Importantly, our model captures tumor interactions with the bone ecosystem and...